10 results about "Eicosapentaenoic acid" patented technology

The invention belongs to the technical field of biology, and particularly relates to a preparation method and application of tumor infiltrating lymphocytes. Keratinase modified by myristoyl coenzyme A cooperates with fibronectin and elastase, so that tumor cells quickly fall off from tumor blocks, and loose tissues are subjected to low-temperature enzymolysis by protease-K, so that the phenotype and activity of tumor infiltrating lymphocytes can be protected; an eicosapentaenoic acid solution is mixed with polysorbate, ultrapure water and a culture medium matrix to obtain an emulsion mixed solution, the emulsion mixed solution is subjected to rotary evaporation to remove a solvent, and the amplification-promoting nanoparticles obtained after freeze drying can make tumor infiltrating lymphocytes ingest effective components more quickly; the tumor infiltrating lymphocytes extracted by the invention are high in activity and rapid in proliferation and growth, still have high cell activity after cryopreservation, and have good anti-breast tumor activity.

The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

The present application belongs to the field of microalgae biotechnology, microalgae culture regulation and high-value lipid bio-manufacturing, and specifically relates to a method for improving microalgae biomass and eicosapentaenoic acid (EPA) yield by regulating amino acids, which takes microalgae capable of synthesizing EPA as a culture object, adds exogenous amino acids or amino acid combinations to the culture system under non-stress culture conditions containing sufficient inorganic nitrogen source, regulates photosynthesis, growth metabolism and lipid synthesis process of the microalgae, and simultaneously improves microalgae biomass and EPA volumetric yield; by adding specific exogenous amino acids or amino acid combinations under the condition of sufficient nutrition culture, the present application realizes synchronous promotion of microalgae growth and EPA accumulation. Different from traditional methods of relying on stress such as nitrogen deficiency to induce lipid accumulation, the present application can improve microalgae biomass, photosynthetic performance, pigment yield and EPA volumetric yield without significantly inhibiting cell growth and photosynthetic activity.

The invention discloses a method for improving killing activity of NK cells, and belongs to the technical field of cellular immunity. Carrying out segmented in-vitro culture on the separated NK cells by adopting a specific basic induction culture medium, an activation induction culture medium and an amplification culture medium, wherein recombinant human insulin and sodium selenite are added into the basic induction culture medium; ganoderma lucidum polysaccharides, eicosapentaenoic acid, IL-15 and IL-18 are added into the activation and induction culture medium. Salidroside, tea polyphenol, low molecular weight chitosan, IL-2 (interleukin-2), IL-21 (interleukin-21) and SCF (mesenchymal stem cells) are added into the amplification culture medium. According to the method, the killing ability of the NK cells obtained through in-vitro culture on tumor cells and the in-vitro proliferation effect of the NK cells are remarkably improved, the problems that in the prior art, the in-vitro proliferation efficiency of the NK cells is low, and cell activity is difficult to consider are solved, and a foundation is laid for clinical transformation of NK cell immunotherapy.

The invention discloses a culture method of umbilical cord mesenchymal stem cells for treating cognitive impairment, and belongs to the technical field of cell culture. The culture method specifically comprises the following steps: (1) preparing a special culture medium; (2) umbilical cord pretreatment; and (3) cell culture. The traditional Chinese medicine extract (astragaloside), the B cell depleting agent (rituximab and ibrutinib) and the metabolism regulator (eicosapentaenoic acid) are jointly applied to the UC-MSCs in-vitro culture process, the multiplication capacity, the anti-inflammatory characteristic and the neural restoration function of the UC-MSCs can be synergistically enhanced, and therefore the cognitive disorder treatment efficiency of the UC-MSCs is remarkably improved.

The present invention relates to the field of bioengineering, and in particular to the application of miR1858 in the preparation and / or production of eicosapentaenoic acid. The present invention obtains the microchlorophyll miR1858 engineered algae strain through engineering metabolic modification, which has an extremely high level of EPA accumulation, and does not require optimization of the culture process, thereby reducing the culture cost. Different from the previous engineering metabolic means of improving EPA, the present invention performs genetic modification at the non-coding level, and the obtained engineered algae strain can efficiently and stably accumulate EPA. The EPA produced by the miR1858 engineered algae strain of the present invention has the characteristics of being green, environmentally friendly, and healthy, and the production of EPA by the engineered algae strain does not pollute the environment, nor does it damage the ecosystem, and is suitable for large-scale cultivation. Therefore, the engineered algae strain is a potential engineered algae strain for commercial production of EPA.

The invention belongs to the technical field of microorganisms, and discloses a high-yield EPA schizochytrium limacinum strain based on normal-pressure and room-temperature plasma mutagenesis and a preparation method and application thereof.The preparation method comprises the following steps that 1, wild schizochytrium limacinum HX308 growing in an exponential period is selected, and a NaCl salt solution with the mass concentration of 2% is used for preparing a bacterial suspension; (2) carrying out mutagenesis on the bacterial suspension in an ARTP mutagenesis instrument; (3) uniformly coating a screened solid culture medium with the mutagenized strain, and culturing in an incubator at 28 DEG C; (4) selecting strains with the fatality rate of 85% on the screening plate for subsequent fermentation culture, and detecting the yield of EPA (Eicosapentaenoic Acid); and (5) determining the EPA content of the mutant strain through a gas chromatographic method, and screening out the schizochytrium limacinum strain with high yield of EPA. The EPA high-yield strain is finally obtained, the yield reaches 5.72 g / L and is 6.09 times that of a wild type with the yield being 0.94 g / L, and the economic effect is remarkable.

The invention relates to the field of system biology, and discloses a construction method and application of a schizochytrium limacinum enzyme constraint model. Wherein the schizochytrium limacinum is Schizochytrium sp. ATCC 20888 ARTP mutagenic bacteria, the model is used for simulating the change of the EPA yield under the conditions of different nitrogen sources and oxygen absorption rates, and fermentation verification is carried out by controlling the nitrogen source concentration of fermentation liquor used in fermentation, the ventilation volume of a fermentation tank and the rotating speed; in addition, 20 potential targets capable of increasing the yield of EPA are determined through protein demand analysis. The method has a wide prospect for systematically predicting the growth nutritional conditions of schizochytrium limacinum and improving the yield and industrial production of EPA (Eicosapentaenoic Acid).